Search for: [Abstract = "The analysis of 226 patients, treated with MCL in Hematology Clinic UJCM between 1992\-2013, was conducted. 1st line chemotherapy regimens were\: CHOP \+\/\- R in 50%, FC\+\/\-R in 23% and intensive induction treatment with cytarabine in 20%. Consolidation with radioimmunotherapy was administered in 34 cases, in 47 – HDT\/ASCT. MRD was regularly assessed with flow cytometry in 46 patients. In 75% molecular was detected. Pre\-emptive treatment was conducted in 25 cases. 20 of these patients, were treated intensively in the first line, with HDT\/ASCT consolidation. Fist line treatment results were\: ORR in 71,68%, SD in 5,31%. MCL was refractory in 24,78 % of cases. Median PFS was 28,78 months and median OS 49,9. Treatment results were similar to data from multicenter trials. Survival depended on\: type of 1st line treatment and risk factors – MPI. MRD follow\-up with flow cytometry is effective in molecular relapse detection, its implementation has an impact on survival in MCL patients. Pre\-emptive therapy is effective method of MRD \(\-\) re\-achieving \(ORR 80%\). The use of pre\-emptive therapy has a strong impact on OS and PFS among MCL patients, especially in subgroup after consolidation with HDT\/ASCT \(5\-cio letnie OS 100%, vs.65%, PFS 100% vs.45%\)."]

Number of results: 1